505 (b)(2) is a less expensive and faster new drug development pathway that are particularly attractive to a manufacturer with rich experience in developing drug products. The 505(b)(2) NDA can provide a shorter and less-costly drug development program and bring a profitable drug to market more rapidly.

Project Catagory Discovery Pre-IND IND Clinical Phase
Solid tumor HLK-1001 505(b)(2)        
Solid tumor HLK-1002 505(b)(2)      
Autoimmune Disease                    
HLK-6002 505(b)(2)
Additional Pipeline                    
HLK-0002 505(j)  
HLK-010 505(j)  
    HLK-0003   505(j)                

Tel: +86-755-86007001   Email: info@hlkpharma.com